The total return over the past 12 months is -92.21% vs. +16.94% for the S&P 500. So far it's up -78.57% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (92.92%) | (97.87%) | (95.38%) | (80.53%) | N/A | N/A |
| Total Return CAGR | (92.21%) | (97.80%) | (95.30%) | (80.35%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Aptevo Therapeutics Inc. (APVO)
| Year | Start price | End price | APVO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $9.43 | $1.80 | (78.57%) | +14.51% | (93.08%) |
| 2025 | $1,551.60 | $9.43 | (99.41%) | +17.72% | (117.13%) |
| 2024 | $106,080.48 | $1,551.60 | (98.54%) | +24.89% | (123.43%) |
| 2023 | $1,359,705.63 | $106,080.48 | (92.20%) | +26.19% | (118.39%) |
| 2022 | $4,612,449.50 | $1,359,705.63 | (70.52%) | (18.17%) | (52.35%) |
| 2021 | $21,479,832.00 | $4,612,449.50 | (78.53%) | +28.74% | (107.27%) |
| 2020 | $5,374,353.50 | $21,479,832.00 | +299.67% | +18.37% | +281.30% |
| 2019 | $10,420,502.00 | $5,374,353.50 | (48.43%) | +31.22% | (79.65%) |
| 2018 | $34,789,708.00 | $10,420,502.00 | (70.05%) | (4.56%) | (65.49%) |
| 2017 | $20,020,492.00 | $34,789,708.00 | +73.77% | +21.70% | +52.07% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
